Journal: Molecular Medicine Reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586-1-AP) and TYMS rabbit polyclonal antibody (cat. no. 15047-1-AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Quantitative RT-PCR, Standard Deviation, Western Blot, Expressing, Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: OncoTargets and Therapy

Article Title: Exploring Protein Expression Profiles in Lung Cancer Insufficient Microwave Ablation: Implications for Recurrence

doi: 10.2147/OTT.S508577

Figure Lengend Snippet: Differential Expression Proteins

Article Snippet: The primary antibodies used in our study were listed below CTP synthase 1 (CTPS1) (Boster #A06374-2, 1:200), Thymidylate synthetase (TYMS) (Boster #BM5360, 1:100), NME nucleoside diphosphate kinase 3 (NME3) (Proteintech #15136-1-AP, 1:200), Renin binding protein (RENBP) (Bioss #bs-8497R, 1:200), Fucose kinase (FCSK) (Sangon #D127113, 1:300), Pyridoxal phosphatase (PDXP) (Abclonal #A17455, 1:300), and Sulfite oxidase (SUOX) (Proteintech #15075-1-AP, 1:200).

Techniques: Quantitative Proteomics, Binding Assay

Journal: OncoTargets and Therapy

Article Title: Exploring Protein Expression Profiles in Lung Cancer Insufficient Microwave Ablation: Implications for Recurrence

doi: 10.2147/OTT.S508577

Figure Lengend Snippet: Relationship Between DEPs and Prognosis From TCGA Dataset

Article Snippet: The primary antibodies used in our study were listed below CTP synthase 1 (CTPS1) (Boster #A06374-2, 1:200), Thymidylate synthetase (TYMS) (Boster #BM5360, 1:100), NME nucleoside diphosphate kinase 3 (NME3) (Proteintech #15136-1-AP, 1:200), Renin binding protein (RENBP) (Bioss #bs-8497R, 1:200), Fucose kinase (FCSK) (Sangon #D127113, 1:300), Pyridoxal phosphatase (PDXP) (Abclonal #A17455, 1:300), and Sulfite oxidase (SUOX) (Proteintech #15075-1-AP, 1:200).

Techniques:

Journal: OncoTargets and Therapy

Article Title: Exploring Protein Expression Profiles in Lung Cancer Insufficient Microwave Ablation: Implications for Recurrence

doi: 10.2147/OTT.S508577

Figure Lengend Snippet: Differential expression proteins of nucleotide metabolism for predicting survival outcomes. The Kaplan-Meier survival analysis and COX regression analysis were conducted on the CTPS1 ( A ) and TYMS ( B ) using data from the TCGA dataset. ( C ) The distribution of risk scores, survival analysis, and heatmap visualization for patients with a double-gene signature. Upper left: The scatter plot represented the risk score from low to high. Different colors represented different groups. Upper right: Kaplan-Meier survival analysis of the risk model from dataset, comparison among different groups was made by Log rank test. Lower left: the scatter plot distribution represented the risk score of different samples corresponding to the survival time and survival status. The bottom heatmap was the gene expression from the signature. Lower right: the ROC curve of the genes.

Article Snippet: The primary antibodies used in our study were listed below CTP synthase 1 (CTPS1) (Boster #A06374-2, 1:200), Thymidylate synthetase (TYMS) (Boster #BM5360, 1:100), NME nucleoside diphosphate kinase 3 (NME3) (Proteintech #15136-1-AP, 1:200), Renin binding protein (RENBP) (Bioss #bs-8497R, 1:200), Fucose kinase (FCSK) (Sangon #D127113, 1:300), Pyridoxal phosphatase (PDXP) (Abclonal #A17455, 1:300), and Sulfite oxidase (SUOX) (Proteintech #15075-1-AP, 1:200).

Techniques: Quantitative Proteomics, Comparison, Gene Expression